Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Myelodysplastic Syndrome (MDS) Drugs Market Growth Potential: How Will Market Size Shift Through 2030?
The myelodysplastic syndrome (mds) drugs market size has experienced significant expansion in recent years. This growth is anticipated to proceed, with the market value forecast to rise from $3.7 billion in 2025 to $3.98 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.6%. Factors contributing to this historical development include higher diagnosis rates for bone marrow disorders, the availability of hypomethylating agents, an increase in oncology treatment centers, the growing adoption of supportive transfusion therapies, and enhanced awareness of the disease.
The myelodysplastic syndrome (mds) drugs market is projected to experience substantial expansion in the coming years. This market is set to reach $5.56 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. This anticipated growth during the forecast period is driven by several factors, including the increasing development of novel immunomodulatory drugs, the rising embrace of precision medicine in hematology, the expansion of clinical trial pipelines, a growing emphasis on enhancing patient quality of life, and increased healthcare expenditure on rare diseases. Key developments expected during this period involve the increasing utilization of targeted therapeutic regimens, the rising adoption of oral and parenteral combination therapies, a greater focus on personalized treatment methods, the expansion of supportive care therapies, and improved monitoring of treatment outcomes.
Get A Free Sample Report With In-Depth Market Insights:
Myelodysplastic Syndrome (MDS) Drugs Market Growth Backed By Core Demand Fundamentals
A rise in myeloid leukemia cases is anticipated to fuel the expansion of the myelodysplastic syndrome (MDS) drug treatment market. Myeloid leukemia is a type of cancer developing in the bone marrow, impacting cells vital for blood production. Myelodysplastic syndrome (MDS) drugs are designed to enhance bone marrow function by addressing the underlying cause of leukemia, thereby lowering the risk of complications from low blood cell counts, decreasing the necessity for chemotherapy and transplants, and boosting survival rates for individuals with myelodysplastic syndrome (MDS). For example, data from the American Cancer Society, a US-based health organization, indicated that approximately 20,380 cases and 11,310 deaths from acute myeloid leukemia (AML) were projected in adults for 2023. Consequently, the growing frequency of myeloid leukemia occurrences is a significant factor driving the myelodysplastic syndrome (MDS) drug market. The expansion of the myelodysplastic syndrome (MDS) drugs market is anticipated to be fueled by increasing research and development efforts. Research and development encompasses methodical scientific investigations and experiments aimed at discovering, formulating, and refining novel therapeutic agents and treatment methods. This surge in R&D stems from a deeper comprehension of MDS’s molecular origins and genetic mutations, empowering pharmaceutical firms and research bodies to pinpoint new therapeutic targets and devise precise medical strategies for this diverse condition. Elevated research and development directly contributes to market growth by broadening the range of experimental therapies, resulting in new drug approvals that offer more treatment choices for patients unresponsive to standard hypomethylating agent therapy or who need different interventions. As an illustration, the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, reported in February 2025 that U.S. research and development expenditures climbed from $892 billion in 2022 to $940 billion in 2023, signifying a $48 billion increase. Thus, increasing research and development is a key impetus for the myelodysplastic syndrome (MDS) drugs market’s growth.
Myelodysplastic Syndrome (MDS) Drugs Market Segments: Where Is Growth Concentrated?
The myelodysplastic syndrome (mds) drugs market covered in this report is segmented –
1) By Drug Type: Chemotherapy, Immunomodulatory Drugs
2) By Route Of Administration: Oral, Parenteral
3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts
4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents
2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide
Myelodysplastic Syndrome (MDS) Drugs Market Growth Trends Reshaping The Competitive Landscape
Major companies active in the myelodysplastic syndrome (MDS) drugs market are concentrating on developing novel products, such as targeted therapy, to enhance patient outcomes, fulfill specific customer needs, and integrate effectively into the ecosystem. Targeted therapy for myelodysplastic syndromes (MDS) involves employing medications that specifically address genetic mutations or molecular irregularities in cancer cells, with the goal of improving results by selectively attacking abnormal cells while minimizing harm to healthy tissue. For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) who possess an isocitrate dehydrogenase-1 (IDH1) mutation. The efficacy of Tibsovo for this specific new indication was assessed in an open-label, single-arm, multicenter study involving 18 adult patients with relapsed or refractory MDS and an IDH1 mutation.
Myelodysplastic Syndrome (MDS) Drugs Market Key Participants And Competitive Landscape
Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.
View The Full Myelodysplastic Syndrome (MDS) Drugs Market Report:
Myelodysplastic Syndrome (MDS) Drugs Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2025. The regions covered in the myelodysplastic syndrome (mds) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
